Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 10;21(1):155.
doi: 10.1186/s13063-020-4097-6.

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)

Michelle L M Mulder  1   2 , Johanna E Vriezekolk  3 , Nathan den Broeder  3 , Elien A M Mahler  3 , Philip S Helliwell  4 , Frank H J van den Hoogen  3   5 , Alfons A den Broeder  3   5 , Mark H Wenink  3
Affiliations

Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA)

Michelle L M Mulder et al. Trials. .

Abstract

Background: Both methotrexate (MTX) and leflunomide (LEF) are registered and regularly prescribed as first-line treatments for the use in patients with psoriatic arthritis (PsA) and they are occasionally used in combination. However, evidence about their individual, and especially combined efficacy, in PsA is lacking. The aim of this study is to compare the effectiveness and safety of MTX and LEF combination therapy to MTX monotherapy in patients with PsA.

Methods: COMPLETE-PsA is a randomized, placebo-controlled, double-blind clinical trial. Disease-modifying antirheumatic drug (DMARD)-untreated patients (n = 78) with clinical diagnosis of active (i.e. ≥2 swollen joints) PsA will be randomized 1:1 (stratified for high disease activity, Psoriatic Arthritis Disease Activity Score [PASDAS] ≥ 5.4) to the combination or monotherapy. The intervention group receives MTX 25 mg (oral or subcutaneous) once weekly plus LEF 20 mg daily, and the control group receives the same but with placebo instead of LEF daily. Primary endpoint is between-group difference in PASDAS at 16 weeks, adjusted for baseline PASDAS. Key secondary parameters include between-group comparisons in change in Disease Activity in Psoriatic Arthritis (DAPSA) score, skin score, enthesitis score, dactylitis score, and swollen/tender joint count, as well as the proportion of patients fulfilling minimal disease activity (MDA), American College of Rheumatology (ACR) 20/50/70 response criteria at week 16. Furthermore, safety, function and quality of life (Health Assessment Questionnaire [HAQ], Psoriatic Arthritic Impact of Disease [PSAID], Short Form 12 [SF-12]) will be assessed.

Discussion: This is, to our knowledge, the first randomized, placebo-controlled, double-blind clinical trial assessing the effectiveness of MTX and LEF combination therapy in patients with PsA. The study will provide important information for treatment strategies and treatment recommendations.

Trial registration: Dutch Trial Register NTR7632 (3 December 2018). CMO NL66544.091.18 (19 November 2018).

Keywords: Combination therapy; Conventional disease-modifying antirheumatic drug (cDMARD); Leflunomide; Methotrexate; Psoriatic arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
SPIRIT figure trial visits and assessments
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin N Am. 2015;41:545–568. doi: 10.1016/j.rdc.2015.07.001. - DOI - PMC - PubMed
    1. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003;42:778. doi: 10.1093/rheumatology/keg217. - DOI - PubMed
    1. Maese J, Diaz Del Campo P, Seoane-Mato D, Guerra M, Canete JD. Effectiveness of conventional disease-modifying antirheumatic drugs in psoriatic arthritis: a systematic review. Reumatol Clin. 2018;14(2):81–89. doi: 10.1016/j.reuma.2016.10.005. - DOI - PubMed
    1. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499–510. doi: 10.1136/annrheumdis-2015-208337. - DOI - PubMed
    1. Coates LC, Chandran V, Ogdie A, O’Sullivan D, Brooke M, Steinkoenig I, et al. International Treatment Recommendations Update: a report from the GRAPPA 2016 Annual Meeting. J Rheumatol. 2017;44(5):684–685. doi: 10.3899/jrheum.170144. - DOI - PubMed

Publication types

MeSH terms